Amgen (AMGN) Shares are Up 3.85%

Amgen (AMGN) : Traders are bullish on Amgen (AMGN) as it has outperformed the S&P 500 by a wide margin of 1.68% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.3%, relative to the S&P 500. The stock has risen by 3.85% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.38% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.98% and the 50-Day Moving Average is 2.43%.The 200 Day SMA reached 11.03% Amgen Inc. is up 16.27% in the last 3-month period. Year-to-Date the stock performance stands at 8.62%.


Amgen (AMGN) : Average target price received by Amgen (AMGN) is $185.55 with an expected standard deviation of $15.58. The most aggressive target on the stock is $209, whereas the most downbeat target is $157. 11 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. Amgen (NASDAQ:AMGN): The stock opened at $172.59 and touched an intraday high of $173.39 on Friday. During the day, the stock corrected to an intraday low of $171.05, however, the bulls stepped in and pushed the price higher to close in the green at $172.96 with a gain of 0.19% for the day. The total traded volume for the day was 4,028,315. The stock had closed at $172.64 in the previous trading session.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.